(UNCY) Unicycive Therapeutics - Overview
Stock: Kidney Injury, Hyperphosphatemia, Fibrosis, Inflammation
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 107% |
| Relative Tail Risk | -12.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.57 |
| Alpha | -6.72 |
| Character TTM | |
|---|---|
| Beta | 0.836 |
| Beta Downside | 0.157 |
| Drawdowns 3y | |
|---|---|
| Max DD | 91.19% |
| CAGR/Max DD | 0.07 |
Description: UNCY Unicycive Therapeutics December 22, 2025
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a clinical-stage biotech focused on therapies for unmet renal and metabolic indications in the U.S., operating from Los Altos, California since its 2016 incorporation.
Its lead assets are UNI-494, a pro-drug of Nicorandil aimed at acute kidney injury, and Renazorb RZB 012 for hyperphosphatemia in chronic kidney disease patients; both target high-need, high-cost segments where current treatment options are limited.
The company has built a network of licensing and service agreements-including Shilpa Medicare (oxylanthanum carbonate), Sphaera Pharma, Syneos Health, Inotiv, Lee’s Pharmaceutical (HK), and Lotus International-to accelerate development, pre-clinical work, and eventual commercialization.
Key financial and market metrics (as of the latest 10-Q) show a cash runway of roughly $12 million, a market-cap near $55 million, and a burn rate of about $3 million per quarter, giving it roughly four quarters of operating liquidity without additional financing.
Sector-wide, biotech firms developing renal therapeutics benefit from an aging U.S. population (≈ 16 % over 65) and rising CKD prevalence, which together drive a projected CAGR of ~ 7 % for the renal-disease drug market through 2030.
For a deeper, data-driven view of UNCY’s valuation and risk profile, you may find the analyst tools on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -33.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.59 > 0.02 and ΔFCF/TA 9.70 > 1.0 |
| NWC/Revenue: 6542 % < 20% (prev 4042 %; Δ 2500 % < -1%) |
| CFO/TA -0.59 > 3% & CFO -29.8m > Net Income -33.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.1m) vs 12m ago 103.1% < -2% |
| Gross Margin: 1.94% > 18% (prev 0.28%; Δ 166.1% > 0.5%) |
| Asset Turnover: 1.27% > 50% (prev 1.75%; Δ -0.48% > 0%) |
| Interest Coverage Ratio: -335.0 > 6 (EBITDA TTM -20.7m / Interest Expense TTM 63.0k) |
Altman Z'' -14.70
| A: 0.73 (Total Current Assets 50.3m - Total Current Liabilities 13.1m) / Total Assets 50.6m |
| B: -2.24 (Retained Earnings -113.2m / Total Assets 50.6m) |
| C: -0.47 (EBIT TTM -21.1m / Avg Total Assets 44.6m) |
| D: -8.62 (Book Value of Equity -113.1m / Total Liabilities 13.1m) |
| Altman-Z'' Score: -14.70 = D |
What is the price of UNCY shares?
Over the past week, the price has changed by +12.06%, over one month by +18.41%, over three months by +49.33% and over the past year by +9.85%.
Is UNCY a buy, sell or hold?
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the UNCY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 46.5 | 595.1% |
| Analysts Target Price | 46.5 | 595.1% |
| ValueRay Target Price | 7.2 | 7.6% |
UNCY Fundamental Data Overview February 02, 2026
P/S = 23.7535
P/B = 3.8246
Revenue TTM = 568.0k USD
EBIT TTM = -21.1m USD
EBITDA TTM = -20.7m USD
Long Term Debt = 265.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 265.0k USD (from shortTermDebt, last quarter)
Debt = 265.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -42.4m USD (from netDebt column, last quarter)
Enterprise Value = 85.9m USD (128.3m + Debt 265.0k - CCE 42.7m)
Interest Coverage Ratio = -335.0 (Ebit TTM -21.1m / Interest Expense TTM 63.0k)
EV/FCF = -2.87x (Enterprise Value 85.9m / FCF TTM -29.9m)
FCF Yield = -34.79% (FCF TTM -29.9m / Enterprise Value 85.9m)
FCF Margin = -5260 % (FCF TTM -29.9m / Revenue TTM 568.0k)
Net Margin = -5883 % (Net Income TTM -33.4m / Revenue TTM 568.0k)
Gross Margin = 1.94% ((Revenue TTM 568.0k - Cost of Revenue TTM 557.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.70 (Enterprise Value 85.9m / Total Assets 50.6m)
Interest Expense / Debt = 5.66% (Interest Expense 15.0k / Debt 265.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -16.7m (EBIT -21.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.83 (Total Current Assets 50.3m / Total Current Liabilities 13.1m)
Debt / Equity = 0.01 (Debt 265.0k / totalStockholderEquity, last quarter 37.5m)
Debt / EBITDA = 2.05 (negative EBITDA) (Net Debt -42.4m / EBITDA -20.7m)
Debt / FCF = 1.42 (negative FCF - burning cash) (Net Debt -42.4m / FCF TTM -29.9m)
Total Stockholder Equity = 18.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -74.93% (Net Income -33.4m / Total Assets 50.6m)
RoE = -184.1% (Net Income TTM -33.4m / Total Stockholder Equity 18.2m)
RoCE = -114.6% (out of range, set to none) (EBIT -21.1m / Capital Employed (Equity 18.2m + L.T.Debt 265.0k))
RoIC = -91.17% (negative operating profit) (NOPAT -16.7m / Invested Capital 18.3m)
WACC = 8.99% (E(128.3m)/V(128.6m) * Re(9.0%) + D(265.0k)/V(128.6m) * Rd(5.66%) * (1-Tc(0.21)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 128.0%
Fair Price DCF = unknown (Cash Flow -29.9m)
EPS Correlation: -3.09 | EPS CAGR: -6.60% | SUE: -0.92 | # QB: 0
Revenue Correlation: -14.75 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.14 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=7
EPS next Year (2026-12-31): EPS=5.91 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+650.2% | Growth Revenue=+0.0%